A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

Abstract

We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression.

Keywords

Ovarian cancer / PARP inhibitor / BRCA / RAD51C

References

[1] Norquist BM,Harrell MI.Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An nrg oncology/gynecologic oncology group study.Clin Cancer Res2018;24:777-83 PMCID:PMC5815909

[2] Song H,Ramus SJ.Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population.J Clin Oncol2015;33:2901-7 PMCID:PMC4554751

[3] Pennington KP,Harrell MI.Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Clin Cancer Res2014;20:764-75 PMCID:PMC3944197

[4] Norquist BM,Brady MF.Inherited mutations in women with ovarian carcinoma.JAMA Oncol2016;2:482-90 PMCID:PMC4845939

[5] Swisher EM,Oza AM.Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.The Lancet Oncology2017;18:75-87

[6] Domchek SM,Shapira-Frommer R.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.Gynecol Oncol2016;140:199-203 PMCID:PMC4992984

[7] Pujade-lauraine E,Selle F.Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.The Lancet Oncology2017;18:1274-84

[8] Matulonis UA,Domchek SM.Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.Ann Oncol2016;27:1013-9

[9] Swisher EM,Oza AM.Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).Nat Commun2021;12:2487 PMCID:PMC8093258

[10] Chandran EA.Significant tumor response to the poly (ADP-ribose) polymerase inhibitor olaparib in heavily pretreated patient with ovarian carcinosarcoma harboring a germline RAD51D mutation.JCO Precis Oncol2018;2:1-4

[11] National Comprehensive Cancer Network. Clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Available from: https://www.nccn.org/guidelines/category_1 [Last accessed on 15 Apr 2022]

[12] Colombo N,Bois AD.ESMO-ESGO Ovarian Cancer Consensus Conference Working GroupESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.Int J Gynecol Cancer2019;29:728-60